The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Ubrogepant for the Treatment of Migraine.
Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment. ⋯ A higher percentage of participants who received ubrogepant than of those who received placebo had freedom from pain and absence of the most bothersome symptom at 2 hours after the dose. The most commonly reported adverse events were nausea, somnolence, and dry mouth. Further trials are needed to determine the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine. (Funded by Allergan; ClinicalTrials.gov number, NCT02828020.).
-
Editorial Comment
Parting the Clouds over Typhoid with a New Conjugate Vaccine.
-
Comment Letter
Treatment of Hypertension in Patients with Asthma. Reply.